top of page
  • Active, not recruiting

NCT03158688: Phase 3 - Carfilzomib, Daratumumab and Dexa for relapsed Multiple Myeloma. (CANDOR)

Updated: Jun 13, 2022

Phase 3 CANDOR study

Dara-Kd

Kd



Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)


Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.


Sponsor

Amgen


Multiple locations

International study

 

ClinicalTrials.gov Identifier: NCT03158688


Official Title: A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma